drug
Amzeeq
Marketedupdated 3mo agoby $DERM Journey Medical Corp
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 7- tagApproval74 co-mentions · 37 sources
- drugDYNACIN60 co-mentions · 37 sources
- drugMINOCYCLINE HYDROCHLORIDE37 co-mentions · 37 sources
- drugminocycline hydrochloride ER37 co-mentions · 37 sources
- drugminocycline hydrochloride SR37 co-mentions · 37 sources
- tagSmall Molecule37 co-mentions · 37 sources
- drugminocycline37 co-mentions · 37 sources
all catalysts(0)
nothing on the calendar yet
Trials studying Amzeeq
- phase2Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
- EP1Topical Minocycline for CARP
- EP1Effect of Arestin-Enhanced SRP on Periodontal and Glycemic Outcomes in Diabetics
- phase3Efficacy and Safety of Minocycline in Patients With Moderate to Severe Acute Ischemic Stroke
- phase1A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54175446 in Healthy Male Participants
- phase4Scaling and Root Planing (SRP) With and Without Minocycline HCl Microspheres, 1 mg
- phase2Study of Oral Minocycline in Treating Bilateral Cystoid Macular Edema Associated With Retinitis Pigmentosa
- phase1Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Minocin (Minocycline) for Injection in Healthy Adults
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 1, 2030
~4.1 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (21)
- Sep 8, 2037method-of-use (U-2647)US 10398641
- Sep 8, 2037method-of-use (U-2647)US 10849847
- Oct 1, 2030method-of-use (U-2647)US 100860804.1y
- Oct 1, 2030method-of-use (U-2647)US 101372004.1y
- Oct 1, 2030formulationUS 102135124.1y
- Oct 1, 2030formulationUS 102135124.1y
- Oct 1, 2030formulationUS 102654044.1y
- Oct 1, 2030formulationUS 102654044.1y
- Oct 1, 2030method-of-use (U-1631)US 103221864.1y
- Oct 1, 2030method-of-use (U-2647)US 105178824.1y
- Oct 1, 2030method-of-use (U-2647)US 108211874.1y
- Oct 1, 2030method-of-use (U-1631)US 109461014.1y
- Oct 1, 2030method-of-use (U-1631)US 121383114.1y
- Oct 1, 2030formulationUS 88651394.1y
- Oct 1, 2030formulationUS 88651394.1y
- Oct 1, 2030formulationUS 89455164.1y
- Oct 1, 2030formulationUS 89455164.1y
- Oct 1, 2030formulationUS 89928964.1y
- Oct 1, 2030formulationUS 89928964.1y
- Oct 1, 2030formulationUS 96757004.1y
- Oct 1, 2030formulationUS 96757004.1y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 38m ago
Found something off?
comments(0)
5-min edit window · permanent after that